Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Common Equity (2023 - 2025)

Zenas BioPharma has reported Common Equity over the past 3 years, most recently at $242.1 million for Q4 2025.

  • Quarterly results put Common Equity at $242.1 million for Q4 2025, down 22.5% from a year ago — trailing twelve months through Dec 2025 was $242.1 million (down 22.5% YoY), and the annual figure for FY2025 was $242.1 million, down 22.5%.
  • Common Equity for Q4 2025 was $242.1 million at Zenas BioPharma, up from $196.4 million in the prior quarter.
  • Over the last five years, Common Equity for ZBIO hit a ceiling of $359.4 million in Q3 2024 and a floor of -$288.8 million in Q2 2024.
  • Median Common Equity over the past 3 years was $218.0 million (2025), compared with a mean of $66.5 million.
  • Biggest five-year swings in Common Equity: soared 277.73% in 2024 and later crashed 45.35% in 2025.
  • Zenas BioPharma's Common Equity stood at -$225.7 million in 2023, then soared by 238.43% to $312.5 million in 2024, then dropped by 22.5% to $242.1 million in 2025.
  • The last three reported values for Common Equity were $242.1 million (Q4 2025), $196.4 million (Q3 2025), and $239.6 million (Q2 2025) per Business Quant data.